Navigation Links
Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
Date:5/24/2012

LEXINGTON, Ky. (May 24, 2012) David Feola, a University of Kentucky College of Pharmacy faculty member in the Department of Pharmacy Practice and Science, received a five-year, $1.8 million grant from the National Institutes of Health (NIH) to continue his research investigating immune responses in the lungs that will potentially lead to the discovery of medical treatments for patients with cystic fibrosis and other chronic pulmonary inflammatory conditions.

Cystic fibrosis is a life-threatening disease that causes mucus in the lungs to become too thick, which leads to severe pulmonary complications. This disease is one of the most common chronic lung diseases in children and young adults, affecting 30,000 children and adults in the United States and nearly 70,000 people worldwide, according to the Cystic Fibrosis Foundation.

Feola's research lab focuses on the regulatory function of macrophages, an immune cell type that kills invading pathogens and controls inflammation, in patients with chronic pulmonary inflammatory diseases. Cystic fibrosis causes progressive, life-threatening lung damage due in large part to repeated, dysregulated inflammatory responses to bacterial infection. Preliminary research in Feola's lab suggests that inducing specific types of macrophage activation could blunt this dysregulated inflammation. This research will lead to discovery of specific drug targets that could slow or halt this destructive cycle of inflammatory injury and pulmonary function decline in these patients.

"It is our hope that this research funding will provide us a greater understanding on how cystic fibrosis works, discover novel ways of treating the disease, and how we might be able to improve quality of life for these patients," said Feola, who also is a two-time graduate of the UK College of Pharmacy. Feola received his PharmD and PhD from the College.

Feola's grant is an investigator-initiated Research Project (R01) award, which is being funded by NIH's National Institute of Allergy and Infectious Diseases. R01 grant funding has become increasingly competitive due to the nation's current economic condition.

"The funding of this NIH grant is a testament to Dr. Feola's skill, expertise, tenacity and perseverance in pursing this support for his research program," said Linda Dwoskin, Associate Dean for Research for the UK College of Pharmacy. "I am extremely happy for him, his lab and the Pharmacy Practice and Science Department. I look forward to hearing about the great discoveries that result from Dr. Feola's research on cystic fibrosis."


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Related medicine news :

1. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
2. University studies and career expectations of medical students
3. University of Minnesota startup to treat challenging bacterial infection
4. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
5. University of Houston Graduate College of Social Work announces partnership with MD Anderson
6. Neuropsychologist receives University of Houstons highest faculty honor
7. Louisiana Tech University professor earns NSF Early Career Development grant
8. Rice University student engineers automate limb lengthening for kids
9. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
10. University of Cincinnati researchers win $3.7M grant from US Department of Defense
11. Oxford University Press partners with the Physical Society of Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... Wheaton, IL (PRWEB) , ... July 28, 2017 , ... ... recently announced the hiring of associate Jennifer M. Cusack. Ms. Cusack joins ... areas. , Ms. Cusack graduated from Bradley University in Peoria, Illinois, with ...
(Date:7/28/2017)... (PRWEB) , ... July 28, 2017 , ... ... protection and financial planning assistance to families and business owners in and around ... to be held in honor of the Make-A-Wish Foundation. , The Make-A-Wish Foundation ...
(Date:7/27/2017)... ... July 27, 2017 , ... Dr. Adam ... of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing an extensive two-day examination in ... dental implants . Dr. Kimowitz and his partner Dr. Hal Kimowitz, practice ...
(Date:7/27/2017)... ... 27, 2017 , ... TransPanel Volume 4 is a collection of animating panel ... exclusive features transitions that contain between 2 and 6 animated panels. Change the direction ... menus. TransPanel Volume 4 makes editing easy in Final Cut Pro X. , TransPanel ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... services, announces the internal promotion of Elrene Clinkscales to Vice President of Revenue ... & Remittance Management, reporting to Derek Morkel, chief executive officer (CEO). , Elrene ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc ... completing a comprehensive review of its manufacturing network, the ... and distribution facilities in Huntsville, Alabama ... take place over the next 12 to 18 months. ... impacted by declining volumes of commoditized products and these ...
Breaking Medicine Technology: